Chapter 11  ·  Module 3

Statins: Adverse Effects and Special Populations

Visual summary — muscle toxicity, hepatotoxicity, diabetes risk, and monitoring

Statin-Associated Muscle Toxicity — Clinical Spectrum

Most common

Myalgia

  • Muscle pain, aching, weakness
  • No creatine kinase elevation
  • 1–5% in blinded trials (nocebo effect inflates open-label rates)
  • Manage with rechallenge protocol

Uncommon

Myopathy

  • Muscle symptoms plus creatine kinase >10× upper limit of normal
  • ~1 per 10,000 patient-years
  • More common at high doses and with drug interactions
  • Discontinue; rechallenge after creatine kinase normalizes

Rare but serious

Rhabdomyolysis

  • Creatine kinase >40× upper limit of normal
  • Myoglobinuria; acute kidney injury risk
  • ~1–3 per 100,000 patient-years
  • Stop statin immediately; IV fluids; hospitalize

Highest Risk Combination

Gemfibrozil plus any statin: potently raises statin concentrations via multiple pathways, dramatically increasing rhabdomyolysis risk. Use fenofibrate instead when a fibrate is required alongside statin therapy.

Adverse Effects — Key Facts

Liver

Hepatotoxicity

  • True liver injury is rare (~1–3 per 100,000 patient-years)
  • Asymptomatic transaminase elevations are common and self-limited
  • Routine liver function test monitoring NOT required
  • Check alanine aminotransferase at baseline only
  • Safe in non-alcoholic fatty liver disease

Glucose

New-Onset Diabetes

  • ~10–12% relative increase in diabetes risk
  • ~1 extra case per 250–500 patients over 4 years
  • Occurs mainly in patients already at diabetes risk
  • Benefit-risk strongly favors statin continuation
  • Manage diabetes; do not stop statin

Nocebo

Perceived Intolerance

  • Most self-reported muscle symptoms replicated on placebo
  • Negative expectations drive a large proportion of symptoms
  • Rechallenge with different statin often successful
  • Patient education addresses nocebo component

Special Populations — Key Prescribing Rules

Population Statin Use Key Rule
Chronic kidney disease (pre-dialysis) Recommended Cap rosuvastatin at 10 mg for severe chronic kidney disease (eGFR <30). Benefit established; no slowing of kidney disease progression.
Dialysis patients Not initiated Evidence does not support starting statins in patients already on hemodialysis. Continue if started before dialysis.
Pregnancy Contraindicated Mevalonate pathway essential for fetal development. Discontinue at confirmed pregnancy. Avoid during breastfeeding.
Elderly (age ≥75) — secondary prevention Recommended High-intensity statin appropriate. Greatest absolute benefit in highest-risk patients.
Elderly (age ≥75) — primary prevention Individualize Moderate intensity preferred. Factor in frailty, polypharmacy, life expectancy, and patient preference.
Cyclosporine (transplant) Use with caution Prefer pravastatin or fluvastatin. Avoid simvastatin and lovastatin. Dose-reduce atorvastatin and rosuvastatin.

Monitoring Summary

Before starting

Baseline Tests

  • Fasting lipid panel
  • Fasting glucose or hemoglobin A1c
  • Alanine aminotransferase
  • Thyroid-stimulating hormone
  • Medication review for interactions

During therapy

Follow-Up

  • Lipid panel at 4–12 weeks after starting or dose change
  • Annual lipid panel once stable
  • Annual glucose in at-risk patients
  • Liver function tests only if symptoms develop
  • Creatine kinase only if muscle symptoms develop